Humira licensed for use in ankylosing spondylitis

The recombinant human monoclonal antibody Humira (adalimumab) has been approved for the treatment of severe active ankylosing spondylitis in adult patients who have not responded adequately to conventional therapy.

The recommended dose of Humira in ankylosing spondylitis is 40mg administered every other week as a single dose via subcutaneous injection.

In clinical trials, a significant improvement in the condition was seen after 2 weeks of treatment and was maintained through the 24 weeks of the study.

Further information: Abbott Laboratories Ltd, Norden Road, Maidenhead, Berks SL6 4XE. Tel: (01628) 773355.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Trial of interferon beta in COVID-19 patients begins in UK

Trial of interferon beta in COVID-19 patients begins in UK

A global phase III clinical trial to evaluate an inhaled...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New muscle spasm treatment option

New muscle spasm treatment option

Myopridin (pridinol) can be prescribed to treat skeletal...